Evogene (EVGN) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVGN shares.
View EVGN analyst ratings or view top-rated stocks.

2 brokers have issued 12-month price objectives for Evogene's shares. Their EVGN share price forecasts range from $3.00 to $8.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 846.0% from the stock's current price.
View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts.

Evogene's stock was trading at $0.70 at the beginning of the year. Since then, EVGN stock has decreased by 16.9% and is now trading at $0.5814.
View the best growth stocks for 2023 here.

Evogene saw a increase in short interest in May. As of May 15th, there was short interest totaling 288,700 shares, an increase of 13.4% from the April 30th total of 254,500 shares. Based on an average daily trading volume, of 73,300 shares, the short-interest ratio is currently 3.9 days. Approximately 0.7% of the company's stock are sold short.
View Evogene's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 30th 2023.
View our EVGN earnings forecast.

Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings results on Thursday, March, 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.14. The biotechnology company had revenue of $0.66 million for the quarter, compared to the consensus estimate of $0.55 million. Evogene had a negative net margin of 1,184.90% and a negative trailing twelve-month return on equity of 67.04%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evogene investors own include AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Abbott Laboratories (ABT), Acasti Pharma (ACST) and Akari Therapeutics (AKTX).

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

Evogene's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.29%) and Simplex Trading LLC (0.00%).

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVGN stock can currently be purchased for approximately $0.58.

Evogene (NASDAQ:EVGN) has a market capitalization of $23.97 million and generates $1.67 million in revenue each year. The biotechnology company earns $-26,640,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.

The company employs 137 workers across the globe.

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The official website for the company is www.evogene.com. The biotechnology company can be reached via phone at (728) 931-1900, via email at ir@evogene.com, or via fax at 972-8946-6724.